Ephedrine
| Evidence Level: L4 | Predicted Indications: 2 |
Table of Contents
Ephedrine: Nasal cavity disease
One-Sentence Summary
Ephedrine is a sympathomimetic agent originally used for upper respiratory and allergic conditions such as allergic rhinitis, vasomotor rhinitis, bronchitis and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, but this is largely an extension of its existing rhinitis uses. Support is limited to 0 clinical trials and 2 publications, both old and low in quality.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, ephedrine is an alpha- and beta-adrenergic agonist with indirect sympathomimetic activity. Vasoconstriction of the nasal mucosa reduces congestion and oedema, which is plausible for nasal cavity disease.
Nasal cavity disease overlaps heavily with the rhinitis and nasopharyngitis indications ephedrine already carries. The high TxGNN score probably reflects this closeness to existing uses, so this is an extension of known use rather than a genuinely new repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14211229 | 1964 | Clinical testing | Svenska Lakartidningen | Experimental testing of an antihistamine (N-hydroxyethylpromethazine chloride) combined with ephedrine in the nasal cavity. No abstract available |
| 11789239 | 2000 | Preliminary clinical observation | Zhongguo Zhong Xi Yi Jie He Za Zhi | Preliminary observation of a rhinitis spray for chronic rhinitis. Ephedrine’s specific contribution is not shown in the available abstract |
Both publications are early or preliminary, and neither tests ephedrine alone.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 224T | Not available | Not available | Not available |
The licence record has no product name, dosage form or indication text, so the current approved Australian indications cannot be confirmed from the data compiled.
Safety Considerations
- Disease-level cautions (from knowledge graph contraindication links, not label text): hypertension, congestive heart failure, epilepsy, liver disease and liver failure, kidney disease, COPD, hypothyroidism, open-angle glaucoma, peptic ulcer disease, inflammatory bowel disease, pancreatitis, gallbladder disease, thrombocytopenia, porphyria, anxiety and neurotic disorders, and psychotic disorders (including schizophreniform and schizoaffective disorders).
- Drug Interactions (100 recorded; examples shown):
- Major: tramadol, amitriptyline, bupropion, methylene blue
- Moderate: other sympathomimetics and beta-agonists (amphetamine, methylphenidate, salbutamol, formoterol, arformoterol, atomoxetine), beta-blockers (atenolol, acebutolol), and antidiabetic agents (metformin, acarbose, alogliptin, albiglutide)
- Minor: morphine, ascorbic acid
- Related literature signals: reports of ephedrine-induced cardiopathy (1978), ephedrine psychosis (1994), and an interaction with theophylline (1975).
Please refer to the TGA-approved Product Information (PI) for authoritative warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is plausible but largely duplicates existing rhinitis indications. The only support is two old, low-quality publications with no registered trials. The extensive cardiovascular, neurological and interaction risks have not been weighed against any demonstrated benefit.
To proceed, the following is needed:
- Product Information (PI) warnings and contraindications for the Australian ARTG entry, including its dosage form and approved indications
- Mechanism of action data
- Modern controlled studies of ephedrine in nasal cavity disease, compared with current alternatives
- A clear statement of how nasal cavity disease differs from the already-listed rhinitis indications
- A safety assessment covering cardiovascular risk and the major drug interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.